Advancing patient care in neurodegenerative diseases with unmet medical needs

AstraZeneca is committed to discovering and developing compounds to improve patient care in neuroscience.

With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders. 


Collaboration stories

Partnering with influential organisations to extend the reach of our science to more patients and healthcare providers

Our focus on unmet medical needs

More than 450 million people worldwide are affected by mental, neurological or behavioural problems, and the number is steadily rising.

  • Opioid-induced constipation (OIC)

    OIC is a condition caused by prescription opioid pain medicines. Millions of patients are treated with opioids each year.

  • Alzheimer's disease (AD)

    AD is a fatal illness that causes progressive decline in memory and other aspects of cognition.

Opportunities for collaboration

Kate's story

What we're working on

We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.

        Image: Artistic rendering of BACE enzyme.

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Infection, Neuroscience and Gastrointestinal (as at 30 September 2015)

Phase 1

Phase 1

  • ATM AVI targeted serious bacterial infections
  • AZD8108 suicidal ideation
  • MEDI-550 pandemic influenza prophylaxis
  • MEDI1814 Alzheimer’s disease
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI8852 influenza A treatment

Phase 2

Phase 2

  • AZD3241 multiple system atrophy
  • AZD3293 Alzheimer’s disease
  • AZD5847 tuberculosis
  • MEDI7510 prevention of RSV disease in older adults
  • MEDI8897 passive RSV prophylaxis
  • susatoxumab (MEDI4893) hospital-acquired pneumonia / serious S. aureus infection

Phase 3/Reg.*

Phase 3/Reg.*

  • CAZ AVI serious infections, complicated intraabdominal infection, complicated urinary tract infection
  • CAZ AVI hospital-acquired pneumonia/ ventilator-associated pneumonia
  • Zinforo pneumonia/skin infections

LCM Projects

LCM Projects

  • Diprivan conscious sedation
  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Diprivan propofol
  • Movantik/Moventig naloxegol
  • Naropin ropivacaine
  • Seroquel IR quetiapine fumarate
  • Seroquel XR quetiapine fumarate
  • Xylocaine lidocaine
  • Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon zolmitriptan


Events and talks

Hear more about our data, products, and pipeline

Join AstraZeneca

and help us deliver life-changing medicines

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.